VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class: Equity / PHARMACEUTCL ETF
Symbol: PPH
Price per share: $103.17
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 7,887,542
Total reported value: $712,684,853
% of total 13F portfolios: 0%
Share change: -57,049
Value change: -$3,708,634
Number of holders: 124

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

As of 30 Sep 2025, 124 institutional investors reported holding 7,887,542 shares of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH).

Institutional Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	324,677	$33,497,345	+$1,318,497			$103.17	19
2025 Q3	7,887,542	$712,684,853	-$3,708,634	$40,186,317	$3,587,292	$90.36	124
2025 Q2	7,771,917	$683,617,119	+$174,839,485	$41,446,752	$3,316,092	$87.96	126
2025 Q1	5,812,878	$529,776,765	-$16,593,374	$55,607,526	$1,667,679	$91.13	133
2024 Q4	5,968,612	$514,991,591	+$11,463,960	$4,322,628	$1,251,060	$86.28	140
2024 Q3	5,722,368	$543,596,181	+$86,910,938	$693,719	$1,197,378	$95.03	140
2024 Q2	4,815,475	$440,503,835	+$20,148,731	$4,034,268	$976,940	$91.48	139
2024 Q1	4,560,967	$413,738,555	-$6,570,269	$498,850	$1,632,600	$90.70	135
2023 Q4	4,735,950	$385,640,268	-$16,334,775	$4,133,408	$1,155,453	$81.37	108
2023 Q3	5,055,242	$403,877,688	+$20,782,635	$111,804	$551,034	$79.86	101
2023 Q2	4,968,295	$391,351,030	+$6,082,356	$252,064	$779,823	$78.77	101
2023 Q1	4,592,895	$356,545,144	-$174,679,110	$1,016,953	$5,347,387	$77.63	104
2022 Q4	6,556,396	$509,704,617	+$29,919,137	$412,024	$3,288,402	$77.74	111
2022 Q3	6,321,313	$426,561,742	+$118,107,484	$410,000	$7,396,000	$67.24	85
2022 Q2	4,502,840	$345,999,696	+$274,153,350	$1,160,000	$4,826,000	$76.84	90
2022 Q1	882,288	$70,469,084	+$7,531,365	$909,000	$335,000	$79.76	74
2021 Q4	769,399	$59,210,150	-$6,214,856	$1,408,000	$369,000	$76.95	61
2021 Q3	775,415	$56,458,804	+$3,053,753	$2,068,000	$865,000	$72.81	49
2021 Q2	861,370	$62,932,502	-$121,700,494	$731,000	$416,000	$73.07	52
2021 Q1	2,722,467	$187,899,411	+$79,801,407	$41,760,000	$1,118,000	$69.02	51
2020 Q4	1,391,267	$92,698,931	-$36,792,997	$31,676,000	$9,181,000	$66.48	48
2020 Q3	1,950,775	$121,269,474	+$26,966,047	$24,339,000	$361,000	$62.17	46
2020 Q2	1,517,324	$94,463,969	+$34,775,889	$1,619,000	$1,345,000	$62.25	47
2020 Q1	1,060,989	$57,742,871	-$79,299,356	$1,648,000	$2,344,000	$54.39	44
2019 Q4	3,207,826	$205,589,007	+$10,968,047	$1,759,000	$2,606,000	$64.18	48
2019 Q3	2,269,401	$129,276,499	+$52,001,851	$802,000	$819,000	$56.95	43
2019 Q2	952,757	$55,873,605	-$3,054,320	$6,770,000	$1,737,000	$58.67	40
2019 Q1	1,002,623	$60,875,954	-$33,883,025	$473,000	$1,372,000	$60.71	44
2018 Q4	1,560,984	$85,560,052	-$19,773,375	$0	$496,000	$54.79	44
2018 Q3	1,899,381	$122,176,472	-$19,204,656	$1,042,000		$64.34	42
2018 Q2	2,214,462	$130,530,022	+$13,765,279	$920,000	$0	$59.00	48
2018 Q1	1,982,906	$112,643,688	+$23,538,488	$1,651,000	$408,000	$56.82	51
2017 Q4	1,567,774	$93,015,784	-$67,109,351	$339,000	$0	$59.31	49
2017 Q3	2,357,266	$136,154,624	+$67,642,279	$445,000	$312,000	$57.76	46
2017 Q2	1,201,989	$70,984,650	-$41,248,475	$313,000		$59.06	48
2017 Q1	1,901,736	$104,884,746	+$2,251,433			$55.14	49
2016 Q4	1,861,501	$97,792,252	-$64,452,979	$0	$0	$52.51	48
2016 Q3	3,071,963	$176,501,646	+$41,474,999	$454,000	$419,000	$57.45	56
2016 Q2	2,322,425	$136,167,310	+$135,429,458	$2,000		$58.62	52
2016 Q1	10,828	$623,000	+$623,000			$57.52	2